Northwest BiotherapeuticsNWBO
13F holders, Q4 2024 (December 31)11holders
1new positions
2sold out
$0.28avg. 13F price*
At the end of Q4 2024, 11 institutions reported holding Northwest Biotherapeutics (NWBO) in their 13F filings, unchanged from Q3 2024. 1 opened new positions and 2 sold out. The largest holders were Moloney Securities Asset Management, LLC ($134K), VSM Wealth Advisory, LLC ($18K) and Opus Capital Group, LLC ($17K).
- Company
- Northwest Biotherapeutics
- Filed as
- NW Biotherapeutics (Q4 2024)
- CUSIP
- 66737P600
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 2 | $12K |
All 13F filers, Q3 2024 → Q4 2024: 39,230 shares bought and 48,000 shares sold, net −8,770 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Moloney Securities Asset Management, LLC | 0.02% | Add +5.7% | 488,520 | $134K |
| VSM Wealth Advisory, LLC | 0.01% | — | 65,574 | $18K |
| Opus Capital Group, LLC | 0.00% | No change | 60,150 | $17K |
| Williams Jones Wealth Management, LLC. | 0.00% | Reduce -22.9% | 27,000 | $7K |
| Ethos Financial Group, LLC | 0.00% | No change | 23,700 | $7K |
| AlphaMark Advisors, LLC | 0.00% | No change | 14,007 | $4K |
| Rothschild Wealth LLC | 0.00% | New | 12,925 | $4K |
| Advisors Management Group Inc. | 0.00% | No change | 10,270 | $3K |
| KLCM Advisors, Inc. | 0.00% | No change | 10,000 | $3K |
| Hantz Financial Services, Inc. | 0.00% | No change | 250 | $0 |
| Coston, McIsaac & Partners | 0.00% | No change | 1,000 | $0 |
"% of holder's portfolio" is NWBO's weight in each manager's 13F, not the share of Northwest Biotherapeutics the manager owns.